Prostate specific antigen (PSA)
PSA is a protein identified in the blood which may be useful in the detection of prostate cancer. Under normal circumstances, small amounts of PSA are detected in the blood. The PSA may be elevated in a host of abnormal conditions involving the prostate including inflammation, infection, prostate enlargement and cancer. Using our state-of-the-art PSA analyzer, PSA results are obtained in fifteen minutes before the patient has left the office. The results are reviewed and decisions are made at this time regarding the need for any further testing.
In-office testing of urine for patients with hematuria is available using the Matritech NMP22 Bladderchek test for the diagnosis of possible bladder cancer.
This non-invasive assay is used to detect elevated levels of nuclear matrix proteins from a voided urine sample. The results of the test are often available during the course of the office visit providing helpful information regarding the need for any further testing.
PCA3PLUS is a relatively new genetic test for prostate cancer detection. It is used in conjunction with the PSA in order to identify patients at risk for prostate cancer. This urine based test identifies RNA expression of the PCA3 (DD3) gene, which is specific for prostate cancer.
Method of obtaining urine specimen for processing
The patient is encouraged to drink an 8 ounce glass of water prior to the visit so that the urinary bladder is full on arrival to the office. The prostate is massaged on rectal examination. The patient is then instructed to collect a urine specimen to the halfway mark of a vial.
A buffer preservative is added to the specimen for overnight delivery to Bostwick laboratories in Virginia. Results of the testing are faxed to our office within a week. An explanation of the report and its significance will be discussed with the patient at which time a plan of action will be outlined regarding any need for further testing.